Valion Bio, Inc.
VBIO
$1.10
-$0.01-0.90%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 146.00K | 86.00K | 70.00K | 180.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 146.00K | 86.00K | 70.00K | 180.00K |
| Cost of Revenue | -- | 291.00K | 32.00K | 20.00K | -- |
| Gross Profit | -- | -145.00K | 54.00K | 50.00K | -- |
| SG&A Expenses | 733.00K | 1.48M | 1.33M | 1.22M | -276.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.67M | 2.63M | 2.02M | 1.58M | -302.00K |
| Operating Income | -1.98M | -2.48M | -1.93M | -1.51M | -298.00K |
| Income Before Tax | -1.96M | -2.60M | -1.93M | -1.50M | -292.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.96M | -2.60M | -1.93M | -1.50M | -292.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.85M | -2.60M | -1.93M | -1.50M | -1.48M |
| EBIT | -1.98M | -2.48M | -1.93M | -1.51M | -298.00K |
| EBITDA | -1.97M | -2.48M | -1.93M | -1.51M | -298.00K |
| EPS Basic | -1.14 | -2.00 | -2.19 | -2.52 | -1.46 |
| Normalized Basic EPS | -0.35 | -1.17 | -1.37 | -1.57 | 1.67 |
| EPS Diluted | -1.14 | -2.00 | -2.19 | -2.52 | -1.46 |
| Normalized Diluted EPS | -0.35 | -1.17 | -1.37 | -1.57 | 1.67 |
| Average Basic Shares Outstanding | 1.16M | 1.32M | 881.30K | 596.40K | 287.40K |
| Average Diluted Shares Outstanding | 1.16M | 1.32M | 881.30K | 596.40K | 287.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |